Page last updated: 2024-12-08

4-methoxycinnamaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID641294
CHEMBL ID452173
CHEBI ID196005
SCHEMBL ID514958
MeSH IDM0471747

Synonyms (64)

Synonym
nsc-134287
nsc134287
24680-50-0
cinnamaldehyde, p-methoxy-
nsc-26454
p-methoxycinnamic aldehyde
nsc26454
para-methoxy cinnamic aldehyde
PK04_096267
3-(4-methoxyphenyl)acrylaldehyde
2-propenal, 3-(4-methoxyphenyl)-, (2e)-
inchi=1/c10h10o2/c1-12-10-6-4-9(5-7-10)3-2-8-11/h2-8h,1h3/b3-2
(2e)-3-(4-methoxyphenyl)acrylaldehyde
p-methoxycinnamaldehyde
4-methoxycinnamaldehyde
1963-36-6
GHL.PD_MITSCHER_LEG0.403
trans-p-methoxycinnamaldehyde, >=98%, stabilized
NCGC00171001-01
BRD-K19243101-001-01-6
(e)-3-(4-methoxyphenyl)acrylaldehyde
CHEMBL452173
para-methoxy cinnamaldehyde
BMSE010142
(2e)-3-(4-methoxyphenyl)prop-2-enal
M1012
3-(4-methoxyphenyl)-2-propenal
CHEBI:196005
(e)-3-(4-methoxyphenyl)prop-2-enal
p-methoxy cinnamaldehyde
(e)-3-(4-methoxyphenyl)-acrylaldehyde
methoxycinnamaldehyde, p-
ai3-05957
einecs 217-807-0
nsc 26454
fema no. 3567
trans-4-methoxycinnamaldehyde
54098389bl ,
unii-54098389bl
cinnamaldehyde, p-methoxy-, (e)-
AKOS015851928
trans-p-methoxycinnamaldehyde
(e)-4-methoxycinnamaldehyde
(e)-3-(4-methoxyphenyl)-2-propenal
trans-4-methoxy cinnamaldehyde
SCHEMBL514958
J-501926
DTXSID1044308
(2e)-3-(4-methoxyphenyl)-2-propenal #
mfcd00017343
trans-p-methoxycinnamaldehyde, analytical standard
AT28551
p-methoxy-cinnamaldehyde
3-(4-methoxyphenyl)-(2e)-2-propenal
(2e)-3-(4-methoxyphenyl)-2-propenal
cinnamaldehyde, p-methoxy- (8ci)
Q15410215
FS-4297
EN300-96338
D82618
A880097
ZAA68050
?4-methoxycinnamaldehyde
CS-0144244
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
cinnamaldehydesAn enal based on a cinnamaldehyde skeleton and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's2 (33.33)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]